ReviewFrontiers in microbiology2023
The interplay between the microbiota, diet and T regulatory cells in the preservation of the gut barrier in inflammatory bowel disease.
Review in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06553053 (Acupuncture Reduces Relapse in Patients With Crohn's Disease), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Acupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Review
- A barrier-centered perspective on the gut-barrier-bone axis: a review of the core role of the intestinal barrier and related probiotics with nanocoatings.Archives of microbiology · 2026Review
- Multi-omics analysis identifies gut microbiota-glutamine axis contributing to the pathogenesis of reflux esophagitis.Frontiers in microbiology · 2026Article
- The ethnicity and gut microbiota hypothesis: analyzing multifactorial interactions and their health implications.Frontiers in microbiology · 2026Review
- Gut-derived memory T cells: key mediators of neuroinflammation via the gut-brain axis.Frontiers in medicine · 2026Review
- Exploration of Predictive Factors for Acute Radiotherapy-Induced Gastro-Intestinal Symptoms in Prostate Cancer Patients.Cancers · 2025Article
- Gut Microbiota in the Regulation of Intestinal Drug Transporters: Molecular Mechanisms and Pharmacokinetic Implications.International journal of molecular sciences · 2025Review
- Gut microbiota and inflammatory bowel disease: mechanisms, clinical implications, and future directions.Molecular biology reports · 2025Review
- The Vulnerable Vascular Network: Endothelial Dysfunction as a Central Driver of Intestinal Inflammation-A Systematic Review.Biomedicines · 2025Review
- Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2025Review
- Angiogenic Factors and Inflammatory Bowel Diseases.Biomedicines · 2025Review
- The Impact of Antibiotic Therapy on Intestinal Microbiota: Dysbiosis, Antibiotic Resistance, and Restoration Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- A blood-based liquid biopsy analyzing soluble immune checkpoints and cytokines identifies distinct neuroendocrine tumors.Journal of experimental & clinical cancer research : CR · 2025Article
- Systems biology to unravel Western diet-associated triggers in inflammatory bowel disease.Frontiers in immunology · 2025Review
- Lily polysaccharides alleviate colitis through the microbiota-N8-acetylspermidine-cGAS-STING signaling axis.Frontiers in microbiology · 2025Article
- Fecal microbiota and metabolites in the pathogenesis and precision medicine for inflammatory bowel disease.Precision clinical medicine · 2024Review
- Immunomodulatory Effects of a Probiotic Mixture: Alleviating Colitis in a Mouse Model through Modulation of Cell Activation Markers and the Gut Microbiota.International journal of molecular sciences · 2024Article
- Enteric Nervous System Alterations in Inflammatory Bowel Disease: Perspectives and Implications.Gastrointestinal disorders (Basel, Switzerland) · 2024Article
- Article
- Extracellular Vesicles: Novel Potential Therapeutic Agents in Inflammatory Bowel Diseases.Cells · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is becoming more common in the Western world due to changes in diet-related microbial dysbiosis, genetics and lifestyle. Incidences of gut permeability can predate IBD and continued gut barrier disruptions increase the exposure of bacterial antigens to the immune system thereby perpetuating chronic inflammation. Currently, most of the approved IBD therapies target individual pro-inflammatory cytokines and pathways. However, they fail in approximately 50% of patients due to their inability to overcome the redundant pro inflammatory immune responses. There is increasing interest in the therapeutic potential of T regulatory cells (Tregs) in inflammatory conditions due to their widespread capability to dampen inflammation, promote tolerance of intestinal bacteria, facilitate healing of the mucosal barrier and ability to be engineered for more targeted therapy. Intestinal Treg populations are inherently shaped by dietary molecules and gut microbiota-derived metabolites. Thus, understanding how these molecules influence Treg-mediated preservation of the intestinal barrier will provide insights into immune tolerance-mediated mucosal homeostasis. This review comprehensively explores the interplay between diet, gut microbiota, and immune system in influencing the intestinal barrier function to attenuate the progression of colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.